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Abstract
Background: Technological advances raise the possibility of systematic population-based genetic testing for cancer-predisposing 
mutations, but it is uncertain whether benefits outweigh disadvantages. We directly compared the psychological/quality-of-life 
consequences of such an approach to family history (FH)–based testing.
Methods: In a randomized controlled trial of BRCA1/2 gene-mutation testing in the Ashkenazi Jewish (AJ) population, we compared 
testing all participants in the population screening (PS) arm with testing those fulfilling standard FH-based clinical criteria (FH 
arm). Following a targeted community campaign, AJ participants older than 18 years were recruited by self-referral after pretest 
genetic counseling. The effects of BRCA1/2 genetic testing on acceptability, psychological impact, and quality-of-life measures were 
assessed by random effects regression analysis. All statistical tests were two-sided.
Results: One thousand, one hundred sixty-eight AJ individuals were counseled, 1042 consented, 1034 were randomly assigned 
(691 women, 343 men), and 1017 were eligible for analysis. Mean age was 54.3 (SD = 14.66) years. Thirteen BRCA1/2 carriers were 
identified in the PS arm, nine in the FH arm. Five more carriers were detected among FH-negative FH-arm participants following 
study completion. There were no statistically significant differences between the FH and PS arms at seven days or three months 
on measures of anxiety, depression, health anxiety, distress, uncertainty, and quality-of-life. Contrast tests indicated that overall 
anxiety (P = .0001) and uncertainty (P = .005) associated with genetic testing decreased; positive experience scores increased 
(P = .0001); quality-of-life and health anxiety did not change with time. Overall, 56% of carriers did not fulfill clinical criteria for 
genetic testing, and the BRCA1/2 prevalence was 2.45%.
Conclusion: Compared with FH-based testing, population-based genetic testing in Ashkenazi Jews doesn’t adversely affect short-
term psychological/quality-of-life outcomes and may detect 56% additional BRCA carriers.
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Important advances in understanding germ-line predisposi-
tion to familial cancer have led to the identification of several 
rare high-penetrance genes causing cancer syndromes: BRCA1/
BRCA2 (familial breast and/or ovarian cancer) and mismatch-
repair genes (Lynch Syndrome). BRCA1/2 carriers have a 50% to 
80% risk of breast cancer, a 20% to 45% risk of ovarian cancer 
(OC), and a 5% to 25% risk of prostate cancer (1–5). Established 
management strategies for high-risk individuals include: 1) risk-
reducing salpingo-oophorectomy (RRSO) to prevent tubal/ovar-
ian cancer (hazard ratio [HR] = 0.21) (which also halves breast 
cancer risk in premenopausal women) (6), 2)  risk-reducing 
mastectomy to prevent breast cancer (7–9), 3) early onset breast 
screening (MRI/mammograms), and 4) preimplantation genetic 
diagnosis.
Within the UK National Health Service (NHS), genetic 
mutation testing is limited to individuals with cancer from 
high-risk families (carrier probability ≥20% in the general 
population and ≥10% in the Jewish population) or individuals 
from families with a confirmed BRCA mutation who request 
referral to specialist genetic clinics. This family history (FH)–
based approach requires individuals/general practitioners to 
recognize and act on a clinically significant FH. Mutation car-
riers who lack/are unaware of their FH, who do not recognize 
the risk associated with FH or are not proactive in seeking 
advice, are inevitably excluded (10–12). Most of these current 
approach–associated limitations could be overcome by sys-
tematic population-based testing. The literature indicates that 
genetic counseling/testing is associated with psychological 
benefits in noncarriers and has no substantial adverse psy-
chological consequences for carriers (8,13). However, available 
data are predominantly from trials in highly selected sam-
ples of individuals with a strong FH of cancer, and the results 
cannot be generalized to the general population. There is no 
established model for population-based testing of dominant 
mutations, and the best way to deliver this service on a popu-
lation basis is unknown.(13)
We describe results from the first phase of a novel rand-
omized controlled trial (RCT), Genetic Cancer Prediction through 
Population Screening (GCaPPS). The objective was to assess 
the benefits/disadvantages of a population-based approach 
to genetic testing for high penetrance–dominant gene muta-
tions compared with the conventional FH-based approach. The 
RCT design provided a basis for comparison of psychological 
and quality-of-life differences between population-based and 
FH-based testing. We based the trial in an Ashkenazi Jewish 
(AJ) community as a population-model and used BRCA1/2-
mutations as our disease-model. These choices were guided by 
the higher prevalence of three BRCA1/2 founder mutations in 
the AJ population.
Methods
Design
GCaPPS is an RCT (ISRCTN73338115) with two arms: population-
screening (PS) arm and family-history (FH) arm. Inclusion crite-
ria were: age greater than 18 years and AJ ethnicity (self-reported 
history, four AJ grandparents). Exclusion criteria were: known 
BRCA mutation, first-degree relative (FDR) of a BRCA carrier or 
previous BRCA testing. This article reports on: 1) founder-muta-
tions detected, 2) acceptability of the test, and 3) psychological 
and quality-of-life impact. Further analysis of uptake of screen-
ing/preventive strategies is in progress.
Participants
Participants were recruited via the North-London Jewish com-
munity, following a broad-based consultation with key stake-
holders of the AJ community and publicity about the program.
Recruitment
Recruitment was by self-referral. Study information/leaflets 
were made available through community charities, religious 
groups, a pharmacy chain (Boots), and website (www.gcapps.
org). Volunteers received structured, nondirective pretest genetic 
counseling for informed decision-making between October 2008 
and July 2010 at six centers, which included a popular high street 
pharmacy chain and Jewish charity community centers, thus 
providing counseling within a novel high street/community-
based setting. Genetic counseling was undertaken by a qualified 
genetic counselor with supervision from a Regional Genetics 
Centre and a clinical fellow with substantial experience in can-
cer genetics risk assessment and management. It was structured 
to meet the goals of genetic counseling and cancer risk assess-
ment. FH and baseline data were collected at initial appointment. 
Individuals deciding to undergo genetic testing were consented 
postcounseling.
Randomization
Consenting participants were randomly assigned postcoun-
seling using a computer generated random-number algorithm. 
Genetic counselors were blinded to group allocation during 
counseling and recruitment. Participants were informed of their 
randomly assigned allocation by mail.
Genetic Analysis
Genetic testing was performed on all PS-arm volunteers and 
only FH-arm volunteers fulfilling standard FH-based criteria 
(Table  1). This involved sequencing analysis of BRCA1 exons 1 
and 20 and a segment of BRCA2 exon 11 for three Jewish founder 
mutations: 185delAG(c.68_69delAG), 5382insC(c.5266dupC), and 
6174delT(c.5946delT) in an NHS clinical genetics laboratory. Variants 
detected were reconfirmed using a separate aliquot of the original 
DNA sample. We also obtained data on AJ BRCA carriers detected 
through London clinical genetics laboratories from 2000 to 2010.
Test Result Management
Founder mutation–positive (and equivalent number of ran-
domly selected founder mutation–negative) individuals 
received their result at standard face-to-face post-test coun-
seling. Mutation carriers were advised to request referral (via 
general-practitioner) to an NHS regional genetics clinic for con-
firmatory testing and access to established risk-management 
services. Founder mutation–negative volunteers who fulfilled 
standard non-AJ high-risk criteria (Table 1) were also referred to 
genetic clinics. All other founder mutation–negative volunteers 
obtained test results by mail.
Assessment of Demographic, Psychosocial 
Outcomes, and Follow-up
Sociodemographic and FH data were collected using a cus-
tomized questionnaire. Depression and anxiety were assessed 
with the Hospital Anxiety and Depression Scale (HADS) (14). 
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The SF12-questionnaire (Physical Health Component Scale 
[PCS] and Mental Health Component Scale [MCS]) was used to 
assess quality-of-life (15,16). A very short version of the Health-
Anxiety Inventory (HAI) (17) was used to measure health anxi-
ety. The impact of genetic test result disclosure was assessed 
with the distress, uncertainty, and positive-experience scales 
of the Multidimensional Impact of Cancer Risk Assessment 
(MICRA) questionnaire.(18) Data were collected at baseline 
(precounseling), immediately postcounseling (post–decision 
making), and at seven days and, three months after getting the 
test result. Further follow up at one, two, and three years is in 
progress. Details are accessible at: http://www.controlled-trials.
com/ISRCTN73338115. FH-negative FH-arm participants who 
completed the study were offered testing at the end of three-
years of follow-up.
Trial Management
A customized (prototype-based [19,20]) trial management 
system was developed for running/managing the study. This 
included an automated randomization function for group allo-
cation, access to pedigree data, volunteer flagging/tracking, elec-
tronic data upload/access, and upgrade capability for protocol 
development.
Statistical Analysis
Random assignment of 1034 volunteers was completed in July 
2010. The primary comparison is based on an intention-to-treat 
analysis between the PS and FH arms. Baseline characteristics 
were calculated using descriptive statistics.
The questionnaire data were collected over three time points, 
and so to adequately deal with clustered data (within individu-
als over time) a random-effects model (random intercept only) 
with robust standard errors was used to evaluate the effect of 
the intervention (genetic testing) on outcome variables. The 
model included a group effect, time effect, and group-by-time 
interaction. The group-by-time interaction indicates whether 
there is a difference in change over time between groups and 
represents the effect of intervention. Appropriate model-based 
tests/contrasts were used to investigate group and time differ-
ences. Contrast tests were used to compare difference between 
the groups over time points, specifically between time point 1 
vs time point 2 and between time point 1 vs time point 3, as 
well as an overall time effect between groups (contrast of all 
three time points), tested on two degrees of freedom. Additional 
covariables of interest were also included in the model: sex, age, 
FH, income, and marital status. Predicted mean scale scores 
with 95% confidence intervals over all values of group and time 
were plotted, with other covariables set to their mean value. 
Table 1.  High-risk criteria
AJ high-risk criteria for FH-positive group (used in clinical genetics units)
Volunteer should fulfill any one of the following criteria (volunteer/proband should either have been affected by cancer or be a first degree 
relative (FDR) of an affected family member)
1) FDR with breast cancer (<50 years)
2) FDR with ovarian cancer* (any age)
3) Personal history of breast cancer (<50 years)
4) Personal history of ovarian cancer* (any age)
5) FDR with MBC (any age)
6) Personal history (men) of MBC (any age)
* Equivalence of history of ovarian/PPC/FTC for HR criteria
Extended high-risk criteria for referral of FM-negative volunteers to the regional genetic units
Volunteer should fulfill any one of the following criteria (volunteer/proband should either have been affected by cancer or be a FDR of an  
affected family member; criteria should be fulfilled on the same side of the family)
Families with ovarian* cancer (HOC) or breast and ovarian* cancer (HBOC)
1) ≥2 individuals with ovarian cancer* who are FDR
2) 1 ovarian cancer* and 1 breast cancer <50 years who are FDR
3) 1 ovarian cancer* and 2 breast cancers <60 years who are FDR
4) Criteria 1, 2, and 3 can be modified where paternal transmission is occurring ie, families where affected relatives are related by second 
degree through an unaffected intervening male relative and there is an affected sister are eligible
5) Breast cancer in volunteer/proband (≤50 years) and mother (or sister) with both breast and primary ovarian cancer* (in the same person)
Families with breast cancer only (HBC)
6) Breast cancer in volunteer/proband (≤50 years) and any one of the following:
a) breast cancer in mother (age of onset being ≤30 years in one and ≤50 years in the other) or
b) b/l† breast cancer in mother or sister (≤50 years onset of first)
7) ≥4 breast cancers
8) 3 breast cancers related by FDR and
a) 1 ≤30 years or
b) 2 ≤40 years (and all ≤60 years) or
c) 1 MBC (≤60 years) and other 2 ≤50 years
Male breast cancer
9) 2 MBC (≤60 years) in the family, and proband is an FDR of 1 of them
Mutation-positive families
10) Known non-FM in the family
11) Known history of mutation in the family, though unable to trace/identify exact pathogenic mutation and testing negative for 3 FM
* Equivalence of history of ovarian/primary peritoneal cancer/ fallopian tube cancer for high-risk criteria. AJ = Ashkenazi Jewish; b/l = bilateral; FH = family history; 
FM = founder mutation; FTC = fallopian tube cancer; HR = high-risk; MBC = male breast cancer; PPC = primary peritoneal cancer.
† Cases of b/l breast cancer: Each breast cancer may have same count as one relative.
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Statistical analyses used Stata-11.0 (Stata-Corp LP, TX) and R 
(R-Project GNU General-Public-License, Austria, www.R-project.
org) (21). Two-sided P values are reported for all statistical tests.
GCaPPS Phase 1 was powered to assess psychological out-
comes. A sample size of 509/arm had 90% power to detect a 
difference of 1.2 points in total HADS scores between the two 
groups assuming a common SD of 5.9 and α = 0.05.
Results
Between August 2008 and July 2010, 1615 people registered and 
1168 attended genetic counseling. Of these, eight (0.7%) were 
excluded: six FDR of BRCA carriers, two with fewer than four AJ 
grandparents. A total of 1042 (89%) consented to genetic test-
ing, of whom eight withdrew within three weeks, and 1034 (691 
women, 343 men) were randomly assigned to the PS (n = 530) 
or FH (n = 504) arms (Figure 1). Reasons for withdrawal (n = 17) 
included: death (n = 2), death of spouse (n = 1), relocation (n = 1), 
changed mind (n = 4), not wishing to fill more questionnaires/
continue (n = 4), results no longer felt relevant (n = 2), and none 
given (n = 3). A total of 1017 were eligible for analysis.
FH and PS groups were comparable at baseline (Table 2). The 
mean age of participants was 54.3 (SD = 14.66) years; 33.2% were 
men, and 66.8% women. Thirteen (7BRCA1, 6BRCA2) carriers 
were detected in the PS arm (prevalence = 2.45%, 95% confidence 
interval [CI] = 1.31 to 4.16). Of these, only three had a clinically 
significant FH (FH-positive), indicating that 10/13 (77%) carriers 
in the PS arm would not have been detected by FH alone. Nine 
carriers (five BRCA1, four BRCA2) were detected in the FH arm 
(prevalence = 1.79%, 95% CI = 0.82% to 3.36%) (group difference: 
P = .522). Five more carriers were detected among FH-negative 
FH-arm participants following study completion.
The group-by-time interaction effect in the random effects 
model was not statistically significant for outcomes of anxiety, 
depression, quality-of-life, health anxiety, distress, and uncer-
tainty associated with genetic testing (Tables 3 and 4). This indi-
cates that there is no evidence that population-based genetic 
testing has different psychological or quality-of-life effects than 
an FH-based approach over time. The group-by-time interaction 
for positive experience was of borderline statistical significance 
(P = .04), with scores being higher in the population-screening 
arm and for men (Table 4). Modeling showed lower levels of anx-
iety and health anxiety in participants who were older (P = .002) 
and with higher income (P < .0005) and in men compared with 
women (P < .0005) (Tables 3 and 4). Depression was also lower in 
higher income participants (P < .0005) (Table 4). Being married 
and having higher incomes were associated with statistically 
significantly lower levels of distress and uncertainty follow-
ing genetic testing, but this was not affected by sex, age, or FH 
(Table 4).
Contrast tests indicated an overall decrease in anxiety 
(P = .0001), distress (P = .04), and uncertainty (P = .005) with time. 
The majority of decline in anxiety was observed in the baseline 
to seven days (-0.64) period, rather than the seven days to three 
months (-0.24) period. Positive-experience scores increased 
(P = .0001), but quality-of-life and health anxiety did not change 
with time. Predicted mean plots (Supplementary Figures 1–9, 
available online) illustrate these effects. The mean HADS, SF12, 
HAI, and MICRA scores at seven days/three months are given in 
Table 5.
The overall BRCA1/2 prevalence detected was 2.45% (95% 
CI = 1.31% to 4.16%). Of the 1034 participants 128 (12.4%, 95% 
CI = 10.4% to 14.5%) were FH positive. In our sample, the popula-
tion prevalence of FH-positive BRCA carriers (12/1034) was 1.16% 
(95% CI = 0.60% to 2.02%) and the population prevalence of BRCA 
carriers not fulfilling FH-based criteria for testing (FH-negative, 
10/530) was 1.89% (95% CI = 0.91% to 3.44%). To date, 210 of the 
438 FH-negative participants in the FH arm have completed 
three years of follow-up and subsequently opted for genetic 
testing. Five additional BRCA carriers (two BRCA1, three BRCA2) 
have been detected in these 210 participants, giving a total BRCA 
prevalence of 15 of 740 or 2.03% (95% CI = 1.14% to 3.32%) in 
FH-negative individuals. This indicates that a minimum of 15 
of 27 (56%) carriers in this population are not detectable by the 
conventional FH approach, and this figure will rise when the 
remaining 218 FH-negative participants reach three-year follow-
up and are tested. The minimum proportion of carriers detecta-
ble by PS in the overall study population was therefore 27 of 1034 
Figure 1.  Consort flow chart for the study. BL = baseline; DNA = did not attend; FH = family history; FM = founder mutations; GC = genetic counseling; Neg = negative; 
Pos = positive; PS = population screening.
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(prevalence = 2.61%, 95% CI = 1.73% to 3.78%). For 27 BRCA car-
riers in the population, the sensitivity of an FH-based approach 
is 44.4% (95% CI = 26.4 to 63.9%), while the positive (PLR)- and 
negative-likelihood ratios (NLR) are 3.86 (95% CI = 2.2 to 5.81) 
and 0.63 (95% CI = 0.41 to 0.84), respectively. FH details of BRCA 
carriers are given in Supplementary Table 1 (available online).
Discussion
To the best of our knowledge, this is the first population-based 
RCT without ascertainment biased by cancer history in self/
family, comparing FH and population-based approaches for 
testing dominant-gene disorders. While previous single-arm 
studies have suggested that population testing could detect 
more carriers than FH-based testing, they were not designed to 
or able to compare the psychological/quality-of-life implications 
of population-based testing with the current standard of care. 
Our finding of no statistically significant short-term differences 
between FH and population-based approaches with respect to 
levels of anxiety, depression, health anxiety, physical/mental 
well-being, distress, and uncertainty linked to genetic testing is 
reassuring. It confirms that population-based genetic testing in 
the majority of people does not harm quality-of-life or psycho-
logical well-being, or lead to excessive health concerns, and is 
similar to findings among individuals being tested using current 
clinical criteria (8,13,22).
That participation in the program was associated with 
decreases in anxiety and uncertainty linked to genetic testing 
is heartening. This is consistent with many earlier reports that 
identified important psychological benefits of testing (8,13,22,23), 
though a few reports have found increased distress (24). A pop-
ulation-based single-arm study in unselected Canadian Jewish 
women undertaken around the same time as our study reported 
increased levels of cancer-related distress at one year in founder 
mutation–positive but not founder mutation–negative women. 
However, this was not an RCT and did not compare the FH and 
population-screening approaches to genetic testing. In addition, 
none of the women received pretest genetic counselling, though 
93% expressed satisfaction with the testing process (25). Data 
on long-term outcomes from GCaPPS participants are still being 
collected and will be reported in due course.
This is the first report on factors affecting psychological health 
and quality-of-life following genetic testing for cancer-predispos-
ing genes in an unselected population of men and women. FH 
did not affect levels of general anxiety, health anxiety, depres-
sion, quality-of-life, or distress/uncertainty/experience specific to 
genetic testing (Tables 3 and 4). This finding is consistent with an 
earlier study (26) but contrary to another small study (27) report-
ing higher cancer-specific distress at six months in increased-risk 
compared with average-risk participants. In the latter, absolute 
levels of stress were not high and overall stress decreased with 
time (27). Support provided by a spouse and higher income had 
a beneficial impact on anxiety and uncertainty. Our findings are 
largely in agreement with normative data from other popula-
tions (28–30), while few of the variations observed may reflect 
population-based differences in the Ashkenazi UK community. 
It is important to note that though the effects of a number of 
demographic variables on outcomes observed are statistically 
significant, they may reflect a large sample size. Given the modest 
absolute effect sizes, most are unlikely to be clinically relevant.
The decrease in uncertainty (MICRA [18]) specifically associ-
ated with genetic testing and the lack of difference between PS 
and FH groups reconfirms that testing in a low-risk population 
has similar benefits to testing of a high-risk population. The pos-
itive-experience scale is reverse scored and increase in scores 
with time may be related to the possibility of reducing family 
support or relief with the passage of time following receipt of 
test result. This increase was statistically significantly greater 
for men than women (P < .0005) and in those in the population-
screening arm, but not affected by age or FH. These data suggest 
that men and women may respond differently to the experience 
Table 2.  Baseline characteristics of population screening and family 
history arms
Characteristic FH (n = 504) PS (n = 530)
Age
  Mean age, y (SD) 54.30 (14.31) 54.30 (14.99)
Marital status
  Single, % 9.4 9.0
  Married, % 75.5 75.5
  Cohabiting (living with partner), % 4.0 4.4
  Divorced/separated, % 5.6 6.1
  Widowed, % 5.4 5.0
Children
  Have children, % 81.2 82.4
  Number of children (SD) 2.3 (1.28) 2.27 (1.3)
Sex
  Men, % 32.1 34.2
  Women, % 67.9 65.8
Education
  No formal qualification, % 6.8 7.6
  GCSE, O-level, CSE, % 20.7 17.4
  NVQ1, NVQ2, % 1.2 1.4
  A-level, NVQ-3, % 10.2 11.8
  NVQ-4, % 2.5 1.2
  Bachelors, % 37.1 40.7
  Masters, % 16.8 15.6
  PhD, % 4.7 4.4
Income, £
  <10 000, % 4.3 5.1
  10 000–19 900, % 7.2 8.5
  20 000–29 900, % 9.7 9.6
  30 000–39 900, % 12.7 13.0
  40 000–49 900, % 12.9 10.9
  ≥50 000, % 53.2 52.9
Affiliation/identity
  Unaffiliated, % 15.6 14.0
  Liberal, % 10.2 8.2
  Reform, % 16.0 15.1
  Traditional, % 25.5 24.9
  Conservative/Masorti, % 10.0 8.2
  Orthodox, % 22.6 29.5
FH
  FH positive (AJ criteria), %* 13.1 11.7
FH
    FH positive (extended non-AJ criteria), 
%†
3.2 3.0
Psychiatric history
  h/o depression, % 12.9 12.9
  h/o any psychiatric illness, % 5.7 4.3
    h/o medication for psychiatric 
 condition,  %
17.0 14.4
    Current medication for psychiatric 
condition, %
4.9 6.4
* Ashkenazi Jewish criteria: high-risk Ashkenazi Jewish criteria (used for 
randomization), Table 1. AJ = Ashkenazi Jewish; h/o = history of; FH = family 
history; NVQ = National Vocational Qualification; PS = population screening; 
SD = standard deviation.
† Non-AJ criteria: extended high-risk criteria for the general population (see Table 1).
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Table 3.  Random effect models for difference in psychological and quality-of-life outcomes between FH and PS groups over time
Model and variable Coef. Std. Err P>|z| 95% CI
Random effects model for HADS
Group −0.472 0.344 0.169 −1.146 to 0.201
Occasion 2 −0.473 0.484 0.328 −1.422 to 0.475
Occasion 3 −0.881 0.740 0.234 −2.331 to 0.570
Group#Occasion
  1 2 −0.473 0.484 0.328 −1.422 to 0.475
  1 3 −0.881 0.740 0.234 −2.331 to 0.570
Sex −1.292 0.360 <0.0005 −1.997 to −0.587
FH 0.651 0.506 0.198  −0.341 to 1.643
Age −0.035 0.011 0.002 −0.057 to −0.013
Income −0.544 0.128 <0.0005 −0.795 to −0.293
Marital status 0.556 0.460 0.227  −0.345 to 1.458
HADS depression
Group −0.220 0.166 0.184 −0.545 to 0.105
Occasion 2 0.114 0.309 0.711 −0.491 to 0.719
Occasion 3 −0.141 0.392 0.718 −0.910 to 0.627
Group#Occasion
  1 2 −0.330 0.323 0.307 −0.962 to 0.303
  1 3 −0.108 0.405 0.790  −0.901 to 0.685
Sex −0.166 0.173 0.337 −0.505 to 0.173
FH 0.345 0.253 0.173 −0.151 to 0.840
Age −0.002 0.005 0.710 −0.012 to 0.008
Income −0.254 0.064 <0.0005 −0.379 to −0.129
Marital status 0.267 0.223 0.232 −0.171 to 0.705
HADS anxiety
Group −0.252 0.228 0.270 −0.699 to 0.196
Occasion 2 −0.584 0.325 0.072 −1.220 to 0.0526
Occasion 3 −0.738 0.434 0.089 −1.589 to 0.113
Group#Occasion
  1 2 −0.126 0.350 0.719 −0.811 to 0.560
  1 3 −0.315 0.457 0.491 −1.210 to 0.580
Sex −1.129 0.231 <0.0005 −1.582 to −0.676
FH 0.305 0.334 0.361 −0.349 to 0.959
Age −0.033 0.008 <0.0005 −0.048 to −0.018
Income −0.288 0.081 <0.0005 −0.447 to −0.130
Marital status 0.285 0.293 0.331 −0.289 to 0.860
Random effects model for SF12
SF12-MCS
Group 0.373 0.356 0.295 −0.325 to 1.071
Occasion 2 0.493 0.734 0.502 −0.945 to 1.932
Occasion 3 −0.289 0.690 0.676 −1.641 to 1.064
Group#Occasion
  1 2 −0.647 0.784 0.409 −2.183 to 0.889
  1 3 −0.058 0.734 0.937 −1.496 to 1.381
Sex 0.480 0.325 0.141 −0.158 to 1.117
FH −1.007 0.531 0.058 −2.047 to 0.033
Age 0.081 0.011 0.000 0.059 to 0.102
Income 0.084 0.120 0.481 −0.151 to 0.319
Marital status 0.994 0.453 0.028 0.106 to 1.882
SF12-PCS
Group 0.193 0.330 0.558 −0.453 to 0.839
Occasion 2 0.634 0.625 0.311 −0.592 to 1.859
Occasion 3 0.619 0.606 0.307 −0.568 to 1.807
Group#Occasion
  1 2 −0.797 0.669 0.233 −2.108 to 0.514
  1 3 −0.877 0.651 0.178 −2.154 to 0.399
Sex 1.656 0.301 <0.0005 1.066 to 2.246
FH 0.344 0.465 0.460 −0.568 to 1.256
Age −0.092 0.011 <0.0005 −0.115 to −0.070
Income 0.361 0.113 0.001 0.139 to 0.583
Marital status 0.080 0.415 0.846 −0.733 to 0.894
The group-by-time interaction was not statistically significant for any of the models. Reference categories for the following variables is denoted by*: *Group 0 = FH 
(family history); Group 1 = PS (population screening); *Occasion 1 = baseline; Occasion 2 = time point 2 (7 days post test result); Occasion 3 = time point 3 (three 
months post test result); Sex 0 = female; Sex 1 = male; *FH 0 = low risk; FH 1 = high risk. *Marital Status 0 = live alone, ie, single/divorced/widowed; marital Status 
1 = live with partner, ie, married/cohabiting. Income as “continuous variable,” but measured in £10 000 increments. Age in years (continuous variable). Coef = coeffi-
cient; Err = error; FH = family history; Group#Occasion = group-by-time interaction effect; HADS = Hospital Anxiety and Depression Scale; PS = population screening; 
SF12 PCS = SF12 quality-of-life physical component scale; SF12 MCS = SF12 quality-of-life mental component scale; QoL = quality-of-life; Std = standard.
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of receiving genetic test results. It is possible that women and 
those with a strong FH feel more supported/relieved. This find-
ing has not been reported before in a population-based setting. 
While the scores are useful for monitoring, the thresholds of 
clinical significance are unknown. The interpretation of these 
findings is limited by the MICRA development methodology, 
which was based solely on a high-risk population that lacked 
men. Further research into developing and validating instru-
ments specific to genetic testing in low-risk populations is 
warranted.
At least 56% of carriers in our study population would not 
have been detected using traditional clinical criteria. This is also 
the first study to report and confirm that the UK prevalence of 
Jewish BRCA founder mutations is similar to findings from other 
regions (10,31). Our prevalence estimates for FH-positive (1.16%) 
and FH-negative (1.89%) carriers suggest that the proportion of 
undetectable carriers in the entire study population using FH 
alone could reach 63%. This finding is consistent with an initial 
Washington (10) study and with Canadian (32) and Israeli (33) 
single-arm studies undertaken around the time of this trial, in 
Table 4.  Random effects models for health anxiety, distress, uncertainty, and positive experience outcomes*
Model and variable Coef. Std. Err z  P>|z| 95% CI
Random effects model for HAI
 Group −0.088 0.171 −0.510 0.609 −0.423 to 0.248
  Occasion_2 0.167 0.279 0.600 0.549 −0.380 to 0.715
 Occasion_3 −0.037 0.360 −0.100 0.918 −0.743 to 0.669
Group#Occasion†
  1 2 0.019 0.295 0.060 0.949 −0.561 to 0.598
  1 3 0.090 0.372 0.240 0.810 −0.641 to 0.820
Sex −0.486 0.165 −2.950 0.003 −0.809 to −0.163
FH 0.097 0.271 0.360 0.721 −0.434 to 0.629
Age −0.011 0.006 −2.040 0.042 −0.023 to −0.0004
Marital status 0.245 0.213 1.150 0.251 −0.173 to 0.663
Income −0.153 0.061 −2.500 0.012 −0.272 to −0.033
Random effects model for MICRA
MICRA distress
Group −0.790 0.853 −0.930 0.354 −2.461 to 0.881
Occasion_3 −1.159 0.682 −1.700 0.089  −2.495 to 0.177
Group#Occasion‡
1 3 0.945 0.691 1.370 0.172 −0.410 to 2.301
Sex −0.010 0.205 −0.050 0.962  −0.411 to 0.392
FH 0.537 0.494 1.090 0.278  −0.432 to 1.506
Age −0.009 0.010 −0.890 0.376 −0.028 to 0.10
Marital status 0.331 0.113 2.91 0.004  0.108 to 0.553
Income −0.216 0.109 −1.98 0.047 −0.430 to −0.002
MICRA Uncertainty
Group 0.062 1.127 0.060 0.956 −2.148 to 2.272
Occasion_3 −0.474 0.651 −0.730 0.466 −1.750 to 0.802
Group#Occasion‡
1 3 −0.133 0.680 −0.200 0.845 −1.466 to 1.199
Sex −0.389 0.398 −0.980 0.328 −1.169 to 0.391
FH 1.359 0.762 1.780 0.075 −0.135 to 2.853
Age 0.003 0.017 0.210 0.836 −0.029 to 0.036
Marital status 0.635 0.225 2.83 0.005 0.195 to 1.076
Income −0.418 0.18 −2.32 0.02 −0.771 to −0.065
MICRA positive Experience
Group −1.509 1.078 −1.400 0.162 −3.622 to 0.604
Occasion_3 0.915 0.936 0.980 0.328 −0.919 to 2.749
Group#Occasion‡
1 3 2.078 1.010 2.060 0.040 0.097 to 4.059
Sex 3.370 0.607 5.550 <0.0005 2.18 to 4.56
FH −0.746 0.738 −1.010 0.312 −2.193 to 0.700
Age −0.019 0.021 −0.900 0.369 −0.062 to 0.023
Marital status −0.297 0.317 −0.94 0.349 −0.918 to 0.325
Income −0.016 0.177 −0.09 0.927 −0.364 to 0.331
The group-by-time interaction was not significant for the Health Anxiety Inventory scale, the Multidimensional Impact of Cancer Risk Assessment scale (MICRA)–dis-
tress or MICRA-uncertainty models, but was of borderline significance for the MICRA-positive experience model. Reference categories for the following variables is 
denoted by*: *Group 0 = FH (family history); Group 1 = PS (population screening); Occasion 1 = baseline; Occasion 2 = time point 2 (7 days post test result); Occasion 
3 = time point 3 (three months post test result); Sex 0 = female; Sex 1 = male; FH 0 = low risk; FH 1 = high risk; Marital Status 0 = live alone, ie, single/divorced/wid-
owed; Marital Status 1 = live with partner, ie, married/cohabiting; Income as “continuous variable,” but measured in £10 000 increments; Age in years (continuous 
variable). Coef = coefficient; Err = error; FH = family history; Group#Occasion = group-by-time interaction effect; HAI = Health Anxiety Inventory Scale; MICRA = Multi-
dimensional Impact of Cancer Risk Assessment Scale; PS = population screening; REM = random effects model; Std = standard.
† Occasion 1 is the reference variable for HAI random effects model.
‡ Occasion 2 is the reference for MICRA random effects model.
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which 40% (10), 55% (32), and 63% (33) of carriers, respectively, 
lacked a strong FH of cancer. It corroborates data on limited 
family structure (34) and reports from cancer case series unse-
lected for FH, where 50% to 75% of carriers lacked a clinically 
significant FH (11,12,35–38). We estimate that many more carri-
ers could be detected using a PS approach than by conventional 
FH-based testing (2.61% vs 1.16%). Taken together, these data 
clearly illustrate the limitations of the current UK threshold for 
BRCA1/2 genetic testing. Lack of FH may be because of limited 
communication, lack of awareness, inaccuracies in FH, family 
lost in the Holocaust, family migration, small family size, pater-
nal transmission, male preponderance, few women inheriting 
the mutation, and chance.
If the current UK threshold for FH-based testing were relaxed 
to include a BRCA-related cancer (breast/ovary/prostate) in an 
FDR under age 60 years, an FDR at any age, a second-degree 
relative (SDR) under age 60 years or an SDR at any age, then, 
correspondingly, a further two, four, or five founder mutation 
carriers, respectively, would be reclassified as FH positive and 
detected from amongst the current 15 FH-negative volun-
teers (Supplementary Table 1, available online). However, this 
increase in sensitivity from 44.4% to 62.9% would be at the cost 
of a decrease in specificity and a much lower threshold of BRCA 
probability for testing.
The difference in number of FH-positive carriers between 
the FH (9/66) and PS (3/62) arms is likely to be explained by the 
small sample size and chance. The high population prevalence 
of carriers without a strong FH (1.89%) reveals a substantial at-
risk population not detectable using currently available models/
FH-based criteria. It suggests that a population-based approach 
to genetic-testing requires careful consideration. Validation 
studies in high-risk populations show that BRCA risk predic-
tion models are moderately effective in identifying carriers 
(area under the curve [AUC] = 0.67–0.8), are poor at ruling out 
the presence of a mutation (39), underestimate the probability of 
detecting mutations at low (≤10%), and intermediate (10%–40%) 
probability levels, and overestimate mutations at high-probabil-
ity thresholds (40–42). Our findings of a PLR equalling 3.8 and 
an NLR equalling 0.63 reconfirm the poor ability of FH to detect 
BRCA carriers or rule out the presence of a mutation in a pop-
ulation-based cohort. Should the number of carriers be greater 
than 27, the PLR would be even lower and the NLR even higher. 
For comparison, the PLR/NLR for mammography is 9.4/0.19 (43).
Three hundred and twelve BRCA carriers (51% via predic-
tive testing, 49% new mutations) were detected from 2000 to 
2010 through London NHS laboratories using FH-based criteria. 
The total estimated London AJ BRCA carriers eligible for test-
ing (2.45% of 105 600 estimated AJ population >18 years) is 2587. 
Over a period of 10 years, only 12% of these have been identified. 
Although this figure excludes some private sector testing, most 
genetic testing in the UK is undertaken within the NHS. Given 
the options that now exist for cancer risk management and 
prevention, this raises questions about the current FH-based 
approach for identifying people at risk and makes it impera-
tive to explore new approaches for risk prediction. The optimal 
approach adopted will also need to take into account the cost of 
case identification.
There is reasonable acceptability of BRCA testing among 
interested community members. Almost three-quarters (72%) 
of those expressing an interest attended counseling, and the 
majority (89%) consented to testing. Our study has several 
advantages, including the randomized design, high question-
naire response rates, and pretest genetic counseling received 
by participants. We successfully provided counseling within a 
novel community and high street–based setting, away from the 
traditional hospital base. Recently reported population studies 
were single arm and offered counseling only post-testing (32,33). 
Both men and women participated in GCaPPS, and the results 
give an initial estimate of the distribution of people who may 
come forward should BRCA testing be offered on a population 
basis. In keeping with this, the prevalence of psychiatric mor-
bidity (44), levels of anxiety, depression (45), and quality-of-life 
(28,29) in our cohort (Table 2) are similar to reports from UK pop-
ulation-based surveys (44).
While the initial results from our study are promising, the 
study is limited by the small number of carriers and the short-
term follow-up. Some important questions highlighted above 
remain to be answered and longer-term follow-up data evalu-
ated before committing substantial resources to population-
based genetic testing. We have not had sufficient power to 
examine differences in psychological impact or behavioral out-
comes (uptake of screening/preventive options) between BRCA 
carriers detected through FH and population-based approaches. 
These issues will be addressed in the next phase of the trial. 
Participants in our study had higher income and education 
levels, but this is consistent with the income/education levels 
found in the UK Jewish population compared with the general 
population.
There remains some debate on whether mutations detected 
in the setting of a family history will have greater risk than those 
detected in a population without family history. Penetrance 
Table 5.  Mean HADS, SF12, HAI, and MICRA scores at baseline, 7 days 
and 3 months follow up by group*
Mean score FH (n = 504) PS (n = 530)
HADS
HADS total BL (SD) 9.1 (5.3) 8.8 (5.25)
HADS total 7 d (SD) 9.64 (5.04) 7.59 (5.15)
HADS total 3 mo (SD) 9.12 (6.16) 7.3 (5.23)
HADS anxiety BL (SD) 6.16 (3.46) 6.01 (3.61)
HADS anxiety 7 d (SD) 6.04 (3.4) 5.16 (3.42)
HADS anxiety 3 mo (SD) 5.9 (3.72) 4.8 (3.38)
HADS depression BL (SD) 2.94 (2.55) 2.78 (2.45)
HADS depression 7 d (SD) 3.61 (2.76) 2.44 (2.48)
HADS depression 3 mo (SD) 3.22 (3.01) 2.5 (2.55)
SF12 QoL
SF12 physical scale BL (SD) 49.17 (5.15) 49.22 (5.08)
SF12 physical scale 7 d (SD) 49.13 (5.13) 49.01 (5.11)
SF12 physical scale 3 mo (SD) 48.88 (5.41) 48.83 (5.46)
SF12 mental scale BL (SD) 52.14 (5.44) 52.28 (5.49)
SF12 mental scale 7 d (SD) 52.42 (5.28) 52.55 (5.10)
SF12 mental scale 3 mo (SD) 52.16 (5.08) 52.34 (4.95)
vsHAI
vsHAI score BL (SD) 3.1 (2.63) 3.08 (2.51)
vsHAI score 7 d (SD) 3.45 (2.72) 3.18 (2.6)
vsHAI score 3 mo (SD) 3.71 (2.61) 2.99 (2.47)
MICRA
MICRA distress score 7 d (SD) 1.8 (4.43) 0.78 (2.7)
MICRA uncertainty score 7 d (SD) 4.4 (5.97) 2.98 (4.78)
MICRA positive experiences score 7 d (SD) 6.25 (5.49) 6.13 (6.03)
MICRA distress score 3 mo (SD) 1.04 (2.08) 0.59 (2.28)
MICRA uncertainty score 3 mo (SD) 3.71 (4.94) 2.22 (4.39)
MICRA positive experiences score  
3 mo (SD)
7.42 (6.81) 9.06 (7.2)
* BL = baseline; FH = family history; HADS = Hospital Anxiety and Depression 
Scale; HAI = Health Anxiety Inventory; MICRA = Multidimensional Impact of 
Cancer Risk Assessment Scale; PS = population screening; SD = standard devia-
tion; SF12 QoL = SF12 quality-of-life scale.
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estimates may be upwardly biased for mutation carriers in the 
presence of residual familial aggregation if the analytic method 
assumes that disease risk depends on mutation status only. 
Data from the population-based Washington Ashkenazi Study 
corrected for ascertainment (46–48), a meta-analysis of popula-
tion/case-series based data (2), and, more recently, penetrance 
estimates from a single-arm Israeli study (corrected for previous 
potential biases of estimates derived mainly from female carri-
ers) (33) indicate that Jewish BRCA1/BRCA2 carriers ascertained 
on a population basis and those without a strong family his-
tory of cancer have high risks for breast/ovarian cancer, though 
these estimates are clearly lower than estimates obtained from 
high-risk families/cancer genetic clinics.
The whole issue of cancer risk estimation/penetrance is 
complex, and current estimates used in clinical practice are 
derived from models that do not incorporate a number of epi-
demiologic and/or genetic variables that can modify risk. The 
complexities and limitations around risk estimation were 
addressed via individualized pretest genetic counseling under-
taken by counselors with considerable experience in cancer risk 
estimation. While the baseline risk estimates used were based 
on those corrected for population-based ascertainment, the 
volunteer’s family history was reviewed and taken into account 
during this process.
New gene sequencing technologies (49) and the falling cost 
of genetic testing may make it economically feasible to test large 
populations in the future. However, a number of issues related 
to sensitivity, specificity, variants of undetermined significance, 
and non-zero error rate linked to new testing technologies need 
further clarifying and resolving before such an approach can be 
assessed in the non-AJ general population. Our study is limited 
by being specific to the Jewish community and, hence, our find-
ings on uptake, psychological impact, and quality-of-life cannot 
be directly extrapolated/applied to the general non-AJ popula-
tion. While applicability of such an approach to the general non-
AJ population requires more research, our findings are relevant 
to and carry an important message for impact of population-
based testing in Ashkenazi Jews. The lack of detrimental psycho-
logical/quality-of-life outcomes coupled with a health economic 
benefit found in our decision-analytic model has important pol-
icy implications for the AJ population, which can save lives. This 
will require a change in the current paradigm of an FH-based 
approach to genetic testing in this population. Efficient, accept-
able, and more cost-effective ways of delivering information on 
genetic risk on a population basis will also be necessary for this 
and require future research.
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